A Retrospective Review of the Clinical Experience of Linezolid with or Without Rifampicin in Prosthetic Joint Infections Treated with Debridement and Implant Retention
详细信息 查看全文
- 作者：Laura Morata (1)
Eric Senneville (2)
Louis Bernard (3)
Sophie Nguyen (2)
Rodolphe Buzelé (3)
Jérome Druon (4)
Eduard Tornero (1)
Josep Mensa (1)
Alex Soriano (1) - 关键词：Debridement ; Infectious diseases ; Linezolid ; Prosthetic joint infection ; Rifampicin ; Treatment outcome
- 刊名：Infectious Diseases and Therapy
- 出版年：2014
- 出版时间：December 2014
- 年：2014
- 卷：3
- 期：2
- 页码：235-243
- 全文大小：483 KB
- 参考文献：1. Cobo J, Miguel LGS, Euba G, et al. Early prosthetic joint infection: outcomes with debridement and implant retention followed by antibiotic therapy. Clin Microbiol Infect. 2011;17:1632-. CrossRef
2. Vilchez F, Martínez-Pastor JC, Garcia-Ramiro S, et al. Outcome and predictors of treatment failure in early post-surgical prosthetic joint infections due to / Staphylococcus aureus treated with debridement. Clin Microbiol Infect. 2011;17:439-4. CrossRef
3. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA. 1998;279:1537-1. CrossRef
4. Lora-Tamayo J, Murillo O, Iribarren JA, et al. A large multicenter study of methicillin susceptible- and methicillin resistant- / Staphylococcus aureus prosthetic joint infections managed with implant retention. Clin Infect Dis. 2012;56:182-4. CrossRef
5. Senneville E, Joulie D, Legout L, et al. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to / Staphylococcus aureus. Clin Infect Dis. 2011;53:334-0. CrossRef
6. Bernard L, Legout L, Zürcher-Pfund L, et al. Six weeks of antibiotic treatment is sufficient following surgery for septic arthroplasty. J Infect. 2010;61:125-2. CrossRef
7. Livermore DM. Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother. 2003;51(Suppl 2):ii9-6.
8. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother. 2003;51(Suppl 2):ii17-5.
9. Kutscha-Lissberg F, Hebler U, Muhr G, K?ller M. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother. 2003;47:3964-. CrossRef
10. Baldoni D, Haschke M, Rajacic Z, Zimmerli W, Trampuz A. Linezolid alone or combined with rifampin against methicillin-resistant / Staphylococcus aureus in experimental foreign-body infection. Antimicrob Agents Chemother. 2009;53:1142-. CrossRef
11. Gandelman K, Zhu T, Fahmi OA, et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid. In silico and in vitro approaches to explain its mechanism. J Clin Pharmacol. 2011;51:229-6. CrossRef
12. Egle H, Trittler R, Kümmerer K, Lemmen SW. Linezolid and rifampin: drug interaction contrary to expectations? Clin Pharmacol Ther. 2005;77:451-. CrossRef
13. Hoyo I, Martínez-Pastor J, Garcia-Ramiro S, et al. Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections. Scand J Infect Dis. 2012;44:548-0. CrossRef
14. Tornero E, García-Oltra E, García-Ramiro S, et al. Prosthetic joint infections due to / Staphylococcus aureus and coagulase-negative staphylococci. Int J Artif Organs. 2012;35:884-2.
15. Bassetti M, Vitale F, Melica G, et al. Linezolid in the treatment of Gram-positive prosthetic joint infections. J Antimicrob Chemother. 2005;55:387-0. CrossRef
16. Rao N, Hamilton CW. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis. 2007;59:173-. CrossRef
17. Bradbury T, Fehring TK, Taunton M, et al. The fate of acute methicillin-resistant / Staph - 作者单位：Laura Morata (1)
Eric Senneville (2)
Louis Bernard (3)
Sophie Nguyen (2)
Rodolphe Buzelé (3)
Jérome Druon (4)
Eduard Tornero (1)
Josep Mensa (1)
Alex Soriano (1)
1. Bone and Joint Infection Unit, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic of Barcelona, C/Villarroel 170, 08036, Barcelona, Spain
2. Lille-Tourcoing French Referent Center for Osteo-articular Infection, Lille University Hospital, Lille, France
3. Infectious Diseases Unit, Tours University Hospital, Tours Cedex, France
4. Regional French Referent Center for Osteo-articular Infection, Tours Cedex, France - ISSN：2193-6382
文摘
Introduction Debridement and prosthesis retention, combined with a prolonged antibiotic regimen including rifampicin, is an accepted therapeutic approach when the duration of symptoms is less than 4?weeks and there are no radiological signs of loosening. The outcome of patients managed with this strategy has been previously assessed in several articles with success rates of 60-0%. This study aims to review the clinical experience with linezolid in 3 different hospitals from Spain and France in patients with prosthetic joint infection (PJI) managed with debridement, retention of the implant and treated with linezolid with or without rifampicin. Methods Patients with an acute PJI who underwent open debridement with implant retention treated with linezolid for more than 7?days in 3 hospitals from Barcelona, Tours and Lille between 2005 and 2011 were retrospectively reviewed. Relevant information about demographics, co-morbidity, type of implant, surgical treatment, microorganism isolated, antimicrobial therapy, adverse events (AEs) and outcomes were recorded from patients. Results A total of 39 patients were retrospectively reviewed. The mean age (SD) was 70.5 (8.8) years and 9 patients had diabetes mellitus (23%). There were 25 (64%) knee prostheses, 13 (33%) hips and 1 shoulder (3%). The median interquartile range (IQR) days from arthroplasty to infection diagnosis was 17 (19-8) and 33 (85%) cases were diagnosed within the first 60?days. The median (IQR) duration of antibiotic treatment was 70.5 (34-6) days and the median (IQR) number of days on linezolid treatment was 44.5 (30-1). AEs were observed in 15 patients (38%), with gastrointestinal complaints in 8 cases and anemia in 5 being the most frequent. After a median (IQR) follow-up of 2.5 (1.8-.6) years, there were 11 failures (28%) (8 relapses and 3 new infections). The failure rate was higher in the rifampicin group (36% vs. 18%) mainly due to a higher relapse rate (27% vs. 12%) although differences were not statistically significant. Conclusion Management of acute PJIs with debridement and retention of the implant linezolid, with or without rifampicin, is associated with a high remission rate and it is an alternative treatment for infections due to fluoroquinolone and/or rifampicin-resistant staphylococci.